Acquired resistance to epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) is a prevalent clinical problem in the management of advanced non‐small‐cell lung cancer (NSCLC) with TKI‐sensitizing mutations in the EGFR gene. Here, EGFR is linked to non-small cell lung carcinoma.